Recycle your Aservo® EquiHaler®
The first veterinary pharmaceutical recycling programme is here…
References
- Couetil, L.L. et al. (2016) ‘Inflammatory airway disease in horses – revised consensus statement’, Journal of Veterinary Internal Medicine, 30, pp.503-515.
- Lavoie, J. P. et al. (2019) 'Effect of different doses of inhaled ciclesonide on lung function, clinical signs related to airflow limitation and serum cortisol levels in horses with experimentally induced mild to severe airway obstruction,' Equine Veterinary Journal, 51(6), pp. 779–786.
- Pirie, R.S. and McGorum, B.C. (2017) ‘Inhalation therapy for equine lower respiratory tract disease’, In Practice, 39, pp. 317-327.
- CVMP assessment report for Aservo® EquiHaler®.
Aservo® EquiHaler® 343 micrograms/actuation inhalation solution for horses contains ciclesonide. For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)). UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746960 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Aservo®EquiHaler® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2023 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: October 2023. UI-EQU-0124-2020. Use Medicines Responsibly.